Beyond angiogenesis: integrating ferroptosis and metabolic rewiring for next-generation RCC therapy

Area of Science:

• Oncology
• Metabolic pathways
• Cell death mechanisms

Background:

• Renal cell carcinoma (RCC) encompasses diverse subtypes with distinct metabolic profiles impacting cancer progression.
• Chromophobe RCC (chRCC) displays unique metabolic vulnerabilities, including mitochondrial dysfunction, altered redox state, and iron dysregulation.
• Ferroptosis, an iron-dependent form of regulated cell death, is highly relevant to RCC due to its metabolic regulation.

Purpose of the Study:

• To review metabolic alterations in RCC, focusing on chRCC.
• To examine the mechanisms and therapeutic potential of inducing ferroptosis in chRCC.
• To explore how metabolic disruptions in chRCC sensitize cancer cells to ferroptosis.

Main Methods:

• Synthesis of current understanding of metabolic changes in RCC.
• Critical examination of ferroptosis mechanisms and therapeutic potential in chRCC.
• Integration of findings from experimental models, translational studies, and clinical observations.

Main Results:

• chRCC exhibits unique metabolic abnormalities, including mitochondrial and iron regulation issues.
• Ferroptosis induction is a metabolically regulated process relevant to RCC.
• Disruptions in mitochondrial function, glutathione metabolism, and iron homeostasis sensitize renal cancer cells to ferroptosis.

Conclusions:

• Ferroptosis is a metabolically driven therapeutic strategy for RCC, particularly chRCC.
• Understanding metabolic vulnerabilities is key to developing effective ferroptosis-inducing therapies.
• Further research is needed to address therapeutic resistance and clinical translation in heterogeneous renal tumors.